Peter Fail, MD
Advanced Heart Failure and Transplant Cardiology · Houma, LANPI 1437156429
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.1%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Medtronic accounts for 61.9% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2021 at $68,355 and has fallen 84.8% since, to $10,397 in 2025.
Across 652 payments — averaging $316.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$128K
- Abbott$47K
- Atricure, Inc.$15K
- Edwards Lifesciences$7K
- Ancora Heart, Inc.$2K
- Boston Scientific$2K
- plus $5K from 28 others
Across 296 payments — averaging $3014.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$307K
- Abbott$180K
- Atricure, Inc.$148K
- Novartis$97K
- Merck$73K
- Edwards Lifesciences$28K
- plus $59K from 6 others
What the payments were for
- Consulting fees$46,97523%
- Speaking & faculty fees$113,65055%
- Grants$890%
- Travel & lodging$20,25410%
- Food & beverage$25,21612%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 278 | $127,544 |
| Abbott | 148 | $47,266 |
| Atricure, Inc. | 4 | $15,000 |
| Edwards Lifesciences | 69 | $7,349 |
| Ancora Heart, Inc. | 13 | $2,256 |
| Boston Scientific | 25 | $2,175 |
| W. L. Gore & Associates, Inc. | 7 | $675 |
| Cardiac Dimensions, Inc. | 3 | $480 |
| Amgen | 15 | $415 |
| Penumbra, Inc. | 5 | $376 |
| E.r. Squibb & Sons, L.L.C. | 12 | $373 |
| Abiomed | 19 | $355 |
| AstraZeneca | 5 | $297 |
| Pfizer | 12 | $208 |
| Angiodynamics, Inc. | 2 | $166 |
| Kestra Medical Technology Services, Inc. | 7 | $131 |
| Shockwave Medical, Inc | 1 | $124 |
| Terumo Medical Corporation | 2 | $120 |
| Astellas Pharma US Inc | 1 | $119 |
| Silk Road Medical, Inc. | 1 | $109 |
| Medicure Pharma Inc. | 1 | $100 |
| Merck | 1 | $91 |
| Imperative Care, Inc | 1 | $71 |
| Boehringer Ingelheim | 5 | $68 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $64 |
| Cardiovascular Systems Inc. | 1 | $60 |
| Johnson & Johnson | 4 | $58 |
| Impulse Dynamics (USA) Inc. | 1 | $29 |
| Contego Medical, Inc | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Cardiva Medical, Inc. | 1 | $20 |
| Gilead | 1 | $18 |
| Celonova Biosciences, Inc. | 1 | $16 |
| Bard Peripheral Vascular, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CoreValve Evolut$48,874
- COREVALVE EVOLUT R$42,770
- MitraClip$17,526
- MitraClip System$16,035
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$7,500
- ATRICLIP LAA EXCLUSION SYSTEM$7,500
- LARIAT RS$7,500
- Mitra Clip system$2,443
- PASCAL$1,392
- AccuCinch$1,086
- AMPLATZER AMULET$1,019
- EVOQUE$880
- Watchman$849
- Edwards SAPIEN 3 Transcatheter Heart Valve$814
- GENERAL - STRUCTURAL HEART$469
- Avalus$455
- GORE TAG Thoracic Endoprosthesis$335
- CAMZYOS$251
- FARXIGA$250
- RUBY Coil$219
How this compares
Too few advanced heart failure and transplant cardiology providers in Louisianato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 904 | $918,872 |
| EntrestoSacubitril/Valsartan | 674 | $791,173 |
| VyndamaxTafamidis | 12 | $452,686 |
| EliquisApixaban | 423 | $428,966 |
| CamzyosMavacamten | 30 | $242,684 |
| FarxigaDapagliflozin Propanediol | 143 | $150,765 |
| Repatha SureclickEvolocumab | 172 | $140,456 |
| Repatha PushtronexEvolocumab | 177 | $137,080 |
| XareltoRivaroxaban | 127 | $130,424 |
| Praluent PenAlirocumab | 38 | $26,346 |
| VerquvoVericiguat | 20 | $21,491 |
| Valsartan | 689 | $18,311 |
| Rosuvastatin Calcium | 1,278 | $17,713 |
| Metoprolol Succinate | 1,274 | $17,319 |
| Ezetimibe | 907 | $16,134 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $68 | $918,872904 claims |
| PfizerVyndamax, Eliquis | $208 | $881,652435 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $373 | $242,68430 claims |
| AstraZenecaFarxiga, Brilinta | $297 | $162,139158 claims |
| Johnson & JohnsonXarelto | $58 | $130,424127 claims |
| MerckVerquvo | $91 | $21,49120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Louisianaon file to place this against a meaningful peer group, so we don't.
Other advanced heart failure and transplant cardiology in Houma
- Shane PrejeanHouma$102K
- Clement EiswirthNew Orleans$277K
- David MollBaton Rouge$55K
- Senthil AnandNew Orleans$51K
- Siby AyallooreOpelousas$45K
- Hector VenturaNew Orleans$39K
- Phillip SmithBaton Rouge$34K
- Sapna DesaiNew Orleans$30K
- John LawrenceLafayette$17K
- Mohammad El BabaShreveport$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.